Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review.

Zhe ZhaoXinfeng WangXiu-Qi BaoJingwen NingMeiyu ShangDan Zhang

Published in: Cancer immunology, immunotherapy : CII (2020)

As a serious adverse event of ICI treatment, APS-2 is presented with abrupt initiation time and rapid development. Physicians should be aware of potential endocrine disorders and continue monitoring hormone status when treating cancer patients with ICIs.

Keyphrases

primary care
papillary thyroid
multiple sclerosis
squamous cell
case report
squamous cell carcinoma
combination therapy
young adults
drug induced
lymph node metastasis
electronic health record